Patient Experience Transitioning to Subcutaneous Therapy in Advanced Melanoma

In this segment, Ms. Haupert shares her personal experience transitioning from intravenous to subcutaneous immunotherapy in the treatment of advanced melanoma. She describes significant challenges with intravenous access due to difficult vein placement, including multiple attempts and associated discomfort, which impacted her overall treatment experience. Upon learning about the subcutaneous option, she actively pursued the transition in collaboration with her care team. She highlights notable improvements, including reduced time in clinic, shorter administration duration, and greater physical comfort. While intravenous treatment required extended visits due to infusion time and pre-treatment processes, subcutaneous administration allowed for a more streamlined visit with a brief injection. Ms. Haupert also reflects on reduced reliance on supportive medications for discomfort. Dr. Morrison reinforces these observations, emphasizing how differences in administration routes can meaningfully affect patient experience in advanced melanoma care.